Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Epithalon vs NAD+: Mechanism, Biomarker, Application Comparison

Primary Mechanism Activates telomerase (TERT enzyme) to lengthen telomeres at chromosome ends Fuels mitochondrial ATP production and activates sirtuin proteins (SIRT1–7) for DNA repair Non-overlapping pathways. One addresses replicative aging, the other metabo

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Primary Mechanism
  • Activates telomerase (TERT enzyme) to lengthen telomeres at chromosome ends
  • Fuels mitochondrial ATP production and activates sirtuin proteins (SIRT1–7) for DNA repair
  • Non-overlapping pathways. One addresses replicative aging, the other metabolic aging
  • Measurable Biomarker
  • Telomere length (measured via qPCR or flow-FISH). 33% increase demonstrated in published trials
  • Intracellular NAD+/NADH ratio and mitochondrial respiration rates. 60% NAD+ increase with precursor supplementation
  • Both produce quantifiable changes, but telomere testing is less accessible than metabolic panels
  • Optimal Application
  • Replicative senescence prevention in immune cells, vascular endothelium, and stem cell populations
  • Energy deficiency, cognitive decline, metabolic dysfunction, exercise recovery
  • Use epithalon for cellular aging; NAD+ for functional decline
  • Administration Route
  • Subcutaneous injection (typical protocol: 5–10mg daily for 10–20 days, cycled every 3–6 months)
  • Oral precursors (NR/NMN 250–1000mg daily) or IV infusion (500–1000mg weekly)
  • Epithalon requires injection cycles; NAD+ allows daily oral dosing
  • Evidence Depth
  • 40+ peer-reviewed studies, primarily from Russian gerontology institutes. Limited independent replication
  • 200+ studies across multiple institutions globally. Broader research base but mixed clinical outcomes
  • NAD+ has more institutional backing; epithalon has longer observational follow-up
  • Cost Comparison (2026)
  • $80–$150 per 10-day cycle (research-grade peptide from 503B facilities)
  • NR/NMN supplements: $40–$80/month; IV NAD+: $200–$400 per session
  • Epithalon is episodic cost; NAD+ is ongoing monthly expense